{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:23:36Z","timestamp":1790969016020,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1002\/hem3.70246","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T21:57:56Z","timestamp":1761688676000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Overall survival outcomes with first\u2010line continuous ibrutinib and fixed\u2010duration ibrutinib\u2010venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age\u2010matched European population"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"first","affiliation":[{"name":"Universit\u00e0 Vita\u2010Salute San Raffaele Milan Italy"},{"name":"IRCCS Ospedale San Raffaele Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-7261","authenticated-orcid":false,"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer Toulouse Oncopole Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-412X","authenticated-orcid":false,"given":"Ann","family":"Janssens","sequence":"additional","affiliation":[{"name":"UZ Leuven Gasthuisberg Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-9296","authenticated-orcid":false,"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Division of CLL, Department of Internal Medicin III Ulm University Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Fouad","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Middle East FZ\u2010LLC Dubai United\u00a0Arab\u00a0Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-4676","authenticated-orcid":false,"given":"Claudio A.","family":"Schioppa","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-757X","authenticated-orcid":false,"given":"Jos\u00e9\u2010\u00c1ngel","family":"Hern\u00e1ndez\u2010Rivas","sequence":"additional","affiliation":[{"name":"Hospital Universitario Infanta Leonor, Universidad Complutense Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"ASST Grande Ospedale Metropolitano Niguarda Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"4","key":"e_1_2_8_2_1","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014a primer","volume":"11","author":"Delgado A","year":"2021","journal-title":"Am J Cancer Res"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a035220"},{"key":"e_1_2_8_4_1","volume-title":"Key statistics for chronic lymphocytic leukemia","year":"2024"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051583"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01259-X"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279012"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7009"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177713"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00452-7"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","unstructured":"NiemannCU MunirT OwenC et al. First\u2010line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): GLOW study 64\u2010month follow\u2010up (FU) and adverse event (AE)\u2010free progression\u2010free survival (PFS) analysis. Presented at: American Society of Hematology; December 7\u201010 2024; San Diego CA.","DOI":"10.1182\/blood-2024-203269"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.74"},{"key":"e_1_2_8_20_1","volume-title":"Global Health Observatory data repository. Life tables by WHO region: Europe","year":"2024"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","unstructured":"BrownJR SeymourJF JurczakW et al. 1009 Fixed\u2010duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first\u2010line treatment of chronic lymphocytic leukemia: interim analysis of the multicenter open\u2010label randomized phase 3 AMPLIFY trial. Presented at: American Society of Hematology; December 7\u201010 2024; San Diego CA.","DOI":"10.1182\/blood-2024-200701"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:15:50Z","timestamp":1761826550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/hem3.70246"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70246","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70246"}}